Pharmacological Strategies for Preventing Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Wei Chen, Xin Tong, Yuhang Liu, Xi Zhang, Siying Zhu, Yanhua Zhou, Yongdong Wu, Ye Zong

Abstract readSystematic ReviewNetwork Meta-Analysis

In one paragraph

Synthesis in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei ChenBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Xin TongBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Yuhang LiuBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Xi ZhangBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Siying ZhuBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Yanhua ZhouBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.

Yongdong WuBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.ORCID 0009-0006-4438-3527

Ye ZongBeijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yong-An Road, Xi-Cheng District, Beijing 100050, China.ORCID 0009-0000-2448-6365

Funding

Beijing Friendship Hospital YYZZ202215National Key R&D Program of China 2023YFC2507300

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Crohn DiseaseSecondary PreventionAdalimumabAzathioprineHumansInfliximabNitroimidazolesRandomized Controlled Trials as TopicRecurrenceAdalimumabAzathioprineInfliximabNitroimidazolesCrohn’s diseasenetwork meta-analysispharmacological preventionpostoperative recurrencetherapeutic efficacy

Identifiers

PMID42195136

DOI10.3390/medicina62050883

PMCPMC13208836

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.